Tiger Balm marketer earns FDA warning
This article was originally published in The Tan Sheet
Executive Summary
Singapore-based Haw Par Healthcare's Tiger Balm Pain Relieving Patch is a misbranded drug because it makes drug claims such as "stimulating blood circulation" and thus cannot be marketed as an OTC, FDA says. Further, the agency found "significant" violations of good manufacturing practices - including failure to set appropriate specifications - during an inspection of Haw Par's facility, FDA said in a July 20 warning letter